What this is
- This review explores the role of in type 2 diabetes mellitus (T2DM), linking it to metabolic dysfunction and aging.
- It discusses how senescent cells contribute to insulin resistance and β-cell dysfunction through inflammatory signaling.
- The review emphasizes the potential of senolytic therapies to target senescent cells as a novel approach to treating T2DM.
Essence
- is a key contributor to metabolic dysfunction in T2DM, primarily through its inflammatory effects. Senolytic therapies, which target and eliminate senescent cells, show promise as a potential treatment strategy, although current human evidence is limited.
Key takeaways
- is linked to insulin resistance and β-cell dysfunction in T2DM. Senescent cells release inflammatory factors that disrupt insulin signaling and promote metabolic decline.
- Senolytic therapies aim to clear senescent cells and have shown positive results in preclinical models, improving insulin sensitivity and β-cell function. However, human studies are limited and primarily focus on safety rather than long-term metabolic outcomes.
- Despite the mechanistic promise of senolytic therapies, no current interventions have demonstrated sustained improvements in glycemic control or long-term clinical outcomes in T2DM, necessitating further research.
Caveats
- Current evidence from human studies is limited to small, early-phase trials that do not assess long-term efficacy or glycemic control. This restricts the ability to draw definitive conclusions about the therapeutic benefits of senolytic therapies.
- Variability in metabolic phenotypes across different animal models and the lack of standardized endpoints in studies complicate the translation of preclinical findings to human applications.
- Potential off-target effects and safety concerns, particularly with first-generation senolytics, raise caution about their use in diverse patient populations with T2DM.
Definitions
- cellular senescence: A state of irreversible cell-cycle arrest that contributes to aging and metabolic dysfunction, characterized by a pro-inflammatory secretory phenotype.
- senolytic therapy: A treatment strategy aimed at selectively eliminating senescent cells to mitigate their negative effects on tissue function and inflammation.
AI simplified
Introduction
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by insulin resistance, β-cell dysfunction, and chronic low-grade inflammation. Despite major therapeutic advances, current treatment strategies primarily address downstream metabolic abnormalities and rarely alter the underlying trajectory of disease progression (1–3). This limitation has prompted increasing interest in upstream biological mechanisms that link metabolic stress to irreversible tissue dysfunction (4).
Cellular senescence has emerged as a unifying biological process connecting aging, obesity, and metabolic disease. Senescent cells accumulate in adipose tissue, liver, skeletal muscle, and pancreatic islets—organs central to glucose homeostasis—where persistent secretion of pro-inflammatory and matrix-remodeling factors collectively termed the senescence-associated secretory phenotype (SASP) disrupts insulin signaling, promotes immune cell infiltration, and accelerates β-cell failure (5). Importantly, even a modest burden of senescent cells can exert disproportionate systemic effects, positioning senescence as a mechanistically distinct contributor rather than a secondary consequence of metabolic dysfunction (6).
While several prior reviews have described associations between senescence and metabolic disease, they have often treated senescence as an epiphenomenon of obesity or aging, or have focused narrowly on individual tissues or molecular pathways. In contrast, the present review advances the field by explicitly reframing T2DM as a disorder arising from the convergence of metabolic stress and biological aging (6). This perspective distinguishes mechanistic plausibility from clinical efficacy, integrates senolytic and senomorphic strategies within a unified disease framework, and critically evaluates human evidence within appropriate translational boundaries.
Rather than proposing senolytics as near−term therapeutic agents, this review establishes a conceptual framework in which type 2 diabetes mellitus is understood as a convergence of metabolic stress and biological aging. This perspective positions cellular senescence as an upstream disease−organizing process that informs future precision−based translational research.
While this review references non-diabetic aging models where mechanistically informative, interpretation remains centered on metabolic disease–specific data relevant to T2DM pathophysiology.
Methodology
This article is a structured narrative review designed to synthesize mechanistic, preclinical, and early translational human evidence linking cellular senescence to type 2 diabetes mellitus (T2DM).
Search strategy and study identification
A comprehensive literature search was conducted using PubMed, Scopus, and Embase covering publications from January 2010 to September 2025. Search terms included combinations of: “cellular senescence,” “senolytics,” “senescence-associated secretory phenotype,” “SASP,” “SCAP,” “type 2 diabetes mellitus,” “insulin resistance,” and “β-cell dysfunction.”
The initial search yielded 1,274 records (PubMed: 512; Scopus: 438; Embase: 324). After removal of duplicates (n=243), 1,031 records underwent title and abstract screening. Of these, 312 articles were selected for full-text review based on relevance to metabolic disease and senescence biology. Ultimately, 148 primary studies were included in the qualitative synthesis, comprising mechanistic in vitro studies, animal models, early-phase human studies, and organ-specific clinical investigations.
Inclusion and exclusion criteria
Included studies met the following criteria:
Original in vitro, in vivo, or human research
Direct evaluation of senescence mechanisms or senolytic interventions relevant to metabolic dysfunction
Published in English between 2010–2025
Excluded:
Narrative reviews, editorials, conference abstracts
Studies not addressing metabolic endpoints or senescence biology
Non-English publications
Dual independent screening was not formally performed given the narrative review design; however, all included studies were cross-validated by senior authors to ensure thematic consistency and scientific rigor.
Evidence synthesis and methodological limitations
Given the heterogeneity of experimental models, endpoints, and clinical designs, quantitative meta-analysis was not feasible. Evidence was therefore synthesized qualitatively with emphasis on mechanistic plausibility, tissue specificity, translational readiness, and safety considerations.
We acknowledge that, as a structured narrative review, this approach does not incorporate formal risk-of-bias assessment or PRISMA-based systematic methodology. Accordingly, conclusions are interpretative and hypothesis-generating rather than definitive.
Study selection and thematic synthesis were independently reviewed by multiple authors. Any discrepancies regarding inclusion eligibility or interpretive emphasis were resolved through structured discussion and consensus among senior investigators. While formal inter-rater reliability metrics were not calculated due to the narrative design, cross-validation was undertaken to ensure conceptual consistency and balanced interpretation of evidence.
Biology of cellular senescence and metabolic disease
Cellular senescence as a biological stress response
Cellular senescence is a stress-induced state of durable cell-cycle arrest triggered by telomere attrition, DNA damage, oxidative stress, mitochondrial dysfunction, or oncogenic signaling (7). While initially protective—limiting malignant transformation and facilitating tissue remodeling—persistent senescence contributes to age-related tissue dysfunction when clearance mechanisms fail (8, 9). Senescent cells are characterized by activation of cell-cycle inhibitors (p16^INK4a, p21^Cip1), altered metabolism, and secretion of SASP factors that remodel local and systemic environments (10).
Link between senescence, metabolic dysfunction, and the rationale for senolytics
Cellular senescence represents a stress-induced state of irreversible cell-cycle arrest accompanied by sustained metabolic activity and inflammatory signaling (5). In metabolically active tissues, the pathological relevance of senescence lies not merely in growth arrest, but in the acquisition of a robust senescence-associated secretory phenotype (SASP), which exerts paracrine and systemic effects on insulin signaling and tissue homeostasis (6, 11).
As illustrated in Figure 1, metabolic stressors—including aging, obesity, chronic hyperglycemia, oxidative stress, and mitochondrial dysfunction—drive the accumulation of senescent cells within adipose tissue, liver, and pancreatic β-cells (15). These senescent cells persist due to activation of senescent cell anti-apoptotic pathways (SCAPs), allowing them to evade immune clearance and progressively accumulate in tissues critical for glucose regulation (16).
Importantly, even a relatively small burden of senescent cells can exert disproportionate metabolic effects through SASP-mediated signaling, establishing cellular senescence as a mechanistically distinct contributor to insulin resistance and β-cell dysfunction (12). This biological framework provides the rationale for senolytic therapies, which aim to selectively eliminate senescent cells rather than merely suppress downstream inflammation (17) (Figure 1).
![Senescence–SASP–insulin resistance axis in type 2 diabetes mellitus. Chronic metabolic stressors such as aging, obesity, hyperglycemia, oxidative stress, and mitochondrial dysfunction promote the accumulation of senescent cells in key metabolic tissues, including adipose tissue, liver, and pancreatic β-cells. These senescent cells undergo stable cell-cycle arrest while remaining metabolically active and secrete a senescence-associated secretory phenotype (SASP) composed of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α), chemokines (MCP-1), proteases (MMP-9, MMP-12), and alarmins (HMGB1). Persistent SASP signaling drives chronic low-grade inflammation, disrupts insulin receptor substrate-1 (IRS-1) signaling, impairs adipocyte function, promotes hepatic gluconeogenesis, and accelerates β-cell dysfunction, thereby contributing to the initiation and progression of type 2 diabetes mellitus. Senolytic therapies selectively eliminate senescent cells by targeting senescent cell anti-apoptotic pathways (SCAPs), leading to attenuation of SASP burden, reduction of metabolic inflammation, and partial restoration of insulin sensitivity and β-cell function. This framework highlights cellular senescence as a mechanistically distinct and potentially disease-modifying therapeutic target in T2DM. The mechanistic pathways illustrated are supported by prior experimental and translational studies of SASP-mediated insulin resistance and β-cell dysfunction (,–). TAFs, Telomere-associated foci; SCAPs, senescent cell anti-apoptotic pathways, SASP - senescence-associated secretory phenotype. [5] [12] [14]](https://europepmc.org/articles/PMC13050697/bin/fendo-17-1799261-g001.jpg.jpg "Click to view full size")
Senescence–SASP–insulin resistance axis in type 2 diabetes mellitus. Chronic metabolic stressors such as aging, obesity, hyperglycemia, oxidative stress, and mitochondrial dysfunction promote the accumulation of senescent cells in key metabolic tissues, including adipose tissue, liver, and pancreatic β-cells. These senescent cells undergo stable cell-cycle arrest while remaining metabolically active and secrete a senescence-associated secretory phenotype (SASP) composed of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α), chemokines (MCP-1), proteases (MMP-9, MMP-12), and alarmins (HMGB1). Persistent SASP signaling drives chronic low-grade inflammation, disrupts insulin receptor substrate-1 (IRS-1) signaling, impairs adipocyte function, promotes hepatic gluconeogenesis, and accelerates β-cell dysfunction, thereby contributing to the initiation and progression of type 2 diabetes mellitus. Senolytic therapies selectively eliminate senescent cells by targeting senescent cell anti-apoptotic pathways (SCAPs), leading to attenuation of SASP burden, reduction of metabolic inflammation, and partial restoration of insulin sensitivity and β-cell function. This framework highlights cellular senescence as a mechanistically distinct and potentially disease-modifying therapeutic target in T2DM. The mechanistic pathways illustrated are supported by prior experimental and translational studies of SASP-mediated insulin resistance and β-cell dysfunction (,–). TAFs, Telomere-associated foci; SCAPs, senescent cell anti-apoptotic pathways, SASP - senescence-associated secretory phenotype. [5] [12] [14]
Senescence-associated secretory phenotype as a driver of insulin resistance
The SASP is a complex mixture of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α), chemokines (MCP-1), proteases (MMP-9, MMP-12), pro-fibrotic mediators (PAI-1), and alarmins such as HMGB1 (11). As outlined in Figure 1, sustained SASP signaling is the key mechanism contributing to the relationship between senescent cell accumulation and metabolic pathologic processes (6).
In adipose tissue, SASP factors recruit and activate macrophages, trigger local inflammation and dysregulated adipocyte differentiation leading to decrement of GLUT4 expression and insulin-stimulated glucose uptake (11). In the liver, SASP-mediated inflammation induces hepatic insulin resistance and enhances gluconeogenesis, which, in turn, mediates fasting hyperglycemia. Chronic SASP cytokine exposure in pancreatic islets enhances the onset of β-cell stress, functional exhaustion, and apoptotic loss (15). Together, these effects intersect with inhibition of insulin receptor substrate-1 (IRS-1) signaling and sustained low-grade inflammation (“inflammaging”), a feature of type 2 diabetes mellitus (T2DM). In this way SASP acts as a system-wide amplifier of metabolic dysfunction as opposed to being a local inflammatory phenomenon (13).
Triggers and heterogeneity of senescence in metabolic tissues
The induction of cellular senescence in metabolic tissues is multifactorial and context dependent (15). While chronological aging remains a dominant driver, metabolic stressors such as obesity, hyperinsulinemia, oxidative damage, mitochondrial dysfunction, and DNA damage can induce premature senescence independent of age (15). As summarized schematically in Figure 1, these triggers converge across adipose tissue, liver, and pancreatic β-cells, leading to tissue-specific but interconnected metabolic consequences (18, 19).
Senescent cells arise transiently and are efficiently cleared by immune surveillance, whereas others persist, particularly in the setting of metabolic disease where immune function is impaired. This persistence allows chronic SASP signaling to dominate tissue biology, tipping the balance from adaptive stress responses toward pathological inflammation and metabolic decline (20).
Meanwhile, senescence retains essential physiological roles in tumor suppression, tissue remodeling, and wound healing, underscoring the need for selective—not indiscriminate—therapeutic targeting. This duality reinforces the appeal of senolytic strategies designed to eliminate harmful senescent cell populations while minimizing disruption of beneficial senescence programs (21–23).
Role of senescent cells in insulin resistance and β-cell dysfunction
The accumulation of senescent cells within adipose tissue and pancreatic islets is increasingly recognized as a causal contributor to the two defining features of T2DM: insulin resistance and β-cell dysfunction. As shown in Figure 1, SASP-driven inflammation acts as a common upstream mechanism linking these processes across tissues (6).
In adipose tissue, senescent preadipocytes impair adipogenesis, reduce insulin responsiveness, and promote ectopic lipid deposition in liver and skeletal muscle, exacerbating systemic insulin resistance. Elevated circulating levels of SASP components such as IL-6, IL-1β, MCP-1, and PAI-1 correlate with increased risk of T2DM and its vascular complications (24–27).
Within pancreatic islets, β-cell senescence is characterized by upregulation of cell-cycle inhibitors (p16^INK4a, p21^Cip1), reduced insulin secretory capacity, and impaired regenerative potential. Experimental models demonstrate that clearance of senescent β-cells improves insulin secretion and glucose tolerance, providing direct evidence that senescence contributes to β-cell failure rather than representing a passive marker of disease progression (14, 28–30).
Evidence of cellular senescence in type 2 diabetes
A growing body of evidence shows that, as well as being found in metabolically active tissues, senescent cells are responsible for the pathogenesis and progression of type 2 diabetes mellitus (T2DM) (31). The accumulation of senescent cells in β-cells (32), adipose tissue (33), liver (34), and skeletal muscle (35) hinders metabolic stability, causes tissue inflammation due to its senescence, and intensifies insulin resistance. Further human studies have verified that senescent cell markers such as p16^INK4a, p21^Cip1, and SA-β-gal are consistently elevated in the tissues of people with diabetes and obesity, supporting their importance as disease markers (19, 36) (Table 1).
| Tissue/organ | Key findings | Senescence markers | Senolytic interventions | Therapeutic outcomes | References |
|---|---|---|---|---|---|
| Pancreatic β-cells | Insulin resistance induces β-cell senescence, contributing to T2DM pathogenesis. Clearance of senescent cells improves glucose metabolism and insulin secretion. | p16INK4a, SASP, SA-β-gal | Navitoclax (ABT263); Dasatinib + Quercetin (D+Q) | Improved hyperglycemia, restored β-cell gene expression, reduced blood glucose levels | () [32] |
| Adipose Tissue | Hyperinsulinemia triggers senescence in adipocytes and preadipocytes, leading to inflammation via SASP. Senolytics reduce senescent cell burden. | SA-β-gal, p16INK4a, p21Cip1, γH2AX, cyclin D1, loss of HMGB1 | Dasatinib + Quercetin (D+Q) | Reduced p16INK4a and p21Cip1 cells, decreased SASP (IL-1α, IL-6, MMP-9, MMP-12), correlated with insulin resistance markers | () [33] |
| Liver | Fat accumulation promotes hepatocyte senescence via telomere shortening and DNA damage. Senolytics reduce senescence and SASP. | p21Cip1, p53, SA-β-gal, telomere shortening | Dasatinib + Quercetin (D+Q) | Reduced hyperinsulinemia-induced senescence, decreased SASP, potential for NAFLD/NASH treatment | () [34] |
| Skeletal Muscle | Senescence driven by oxidative stress, inflammation, and mechanical load. Senolytics improve muscle function. | p16INK4a, p21Cip1, SA-β-gal, SASP | Navitoclax (ABT263); Dasatinib + Quercetin (D+Q); Nicotinamide riboside | Reduced SASP, improved treadmill performance, enhanced myogenesis | () [35] |
| Multiple Tissues | Senescent cells contribute to age-related pathologies in T2DM across tissues (e.g., adipose, liver, pancreas, muscle). Clearance extends median lifespan in mice. | SA-β-gal, p16INK4a, TAFs, DDR | INK-ATTAC; Dasatinib + Quercetin (D+Q) | Alleviated renal/hepatic dysfunction, pancreatic degeneration, neurodegeneration, improved physical strength | (,) [19] [36] |
Senolytics: an emerging therapeutic class
Senolytics and their mechanisms of action
This shift from molecular description to biological integration allows cellular senescence to be interpreted not as a secondary epiphenomenon, but as a primary disease−organizing process in type 2 diabetes mellitus. Senolytics work by selectively clearing senescent cells through the disruption of senescent cell anti-apoptotic pathways (SCAPs), which are molecular survival systems that allow these cells to evade programmed cell death and continue accumulating in tissues (37, 38). Using RNA interference and large-scale transcriptomic screening, researchers have identified several major SCAP components, including BCL-2/BCL-XL, PI3K/AKT, and p53/p21/serpin signaling. These pathways play a central role in maintaining the survival of senescent cells and have therefore become attractive therapeutic targets (36, 39). Based on these discoveries, a new generation of senolytic drugs such as Dasatinib, Quercetin, Navitoclax, and Fisetin has been developed to trigger apoptosis specifically in senescent cells while sparing normal, healthy ones (40) (Figure 2, Table 2). The following section provides an overview of these agents and summarizes the most recent preclinical and clinical studies exploring their role in type 2 diabetes mellitus and its related complications (Table 2).
![Senolytic drug classes and targeted senescent cell anti-apoptotic pathways (SCAPs). Senescent cells evade apoptosis through activation of senescent cell anti-apoptotic pathways (SCAPs), including BCL-2/BCL-XL, PI3K/AKT, p53/p21, and ephrin-mediated survival signaling. Senolytic agents selectively disrupt these pathways, triggering apoptosis in senescent cells while largely sparing healthy, proliferating cells. Synthetic agents such as navitoclax and UBX1325 primarily target BCL-xL-dependent survival, whereas dasatinib interferes with tyrosine kinase–associated SCAP signaling. Natural senolytics such as quercetin and fisetin exert pleiotropic effects across PI3K/AKT and oxidative stress–responsive pathways. The diversity of SCAP targeting highlights both the therapeutic promise and toxicity considerations of senolytic strategies in metabolic disease. SCAP pathway targeting mechanisms depicted are derived from experimental senolytic studies and pathway analyses described in prior mechanistic investigations (,–). [36] [41] [44]](https://europepmc.org/articles/PMC13050697/bin/fendo-17-1799261-g002.jpg.jpg "Click to view full size")
Senolytic drug classes and targeted senescent cell anti-apoptotic pathways (SCAPs). Senescent cells evade apoptosis through activation of senescent cell anti-apoptotic pathways (SCAPs), including BCL-2/BCL-XL, PI3K/AKT, p53/p21, and ephrin-mediated survival signaling. Senolytic agents selectively disrupt these pathways, triggering apoptosis in senescent cells while largely sparing healthy, proliferating cells. Synthetic agents such as navitoclax and UBX1325 primarily target BCL-xL-dependent survival, whereas dasatinib interferes with tyrosine kinase–associated SCAP signaling. Natural senolytics such as quercetin and fisetin exert pleiotropic effects across PI3K/AKT and oxidative stress–responsive pathways. The diversity of SCAP targeting highlights both the therapeutic promise and toxicity considerations of senolytic strategies in metabolic disease. SCAP pathway targeting mechanisms depicted are derived from experimental senolytic studies and pathway analyses described in prior mechanistic investigations (,–). [36] [41] [44]
| Senolytic agent | Targeted SCAP pathway | Mechanism of action | Key findings | References |
|---|---|---|---|---|
| Navitoclax (ABT263) | BCL-2/BCL-XL | Inhibits anti-apoptotic proteins, promoting senescent cell apoptosis | Improved glucose metabolism and β-cell function; restored gene expression in insulin-resistant models | () [41] |
| Dasatinib | p53/p21, Ephrin receptors | Tyrosine kinase inhibition; disrupts SCAP pathways | Reduced β-cell and adipose tissue senescence; decreased SASP and inflammatory cytokines | () [42] |
| Quercetin | PI3K, AKT, MDM2, P53, HIF-1α | Natural flavonoid targeting multiple SCAP pathways | Synergistic effect with Dasatinib; reduced p16INK4a and p21CIP1 expression; lowered SASP factors | () [43] |
| Dasatinib + Quercetin (D+Q) | Combined SCAP inhibition | Targets a broader range of senescent cells by complementary pathway inhibition | Significant reduction in senescent cells in adipose tissue and skin; lower IL-1α, IL-6, MMP9, MMP12 levels | () [44] |
| INK-ATTAC Mouse Model | p16Ink4a-positive cells | Genetic removal of senescent cells using inducible caspase-8 system | Improved insulin sensitivity and pancreatic function; delayed aging-related decline | () [45] |
| Fisetin | PI3K/AKT pathway | Inhibiting antiapoptotic pathway and suppresses SASP | Reduced the risk of vascular and ischemic heart disease with a positive reduction in senescence | () [46] |
Potential of senolytics in combination therapy
Combination approaches pairing senolytic agents with established antidiabetic drugs have emerged as a novel therapeutic avenue, aiming to address both metabolic dysfunction and cellular senescence. One of the most promising strategies under exploration involves metformin combined with senolytics, particularly fisetin or dasatinib plus quercetin (D+Q). Metformin, an FDA-approved biguanide, enhances insulin sensitivity, suppresses hepatic gluconeogenesis, and downregulates IGF-1 and mTOR signaling, while inhibiting mitochondrial complex I to reduce endogenous reactive oxygen species (ROS) generation. Preclinical evidence indicates that combining metformin with senolytic agents augments suppression of the senescence-associated secretory phenotype (SASP) and improves mitochondrial function in diabetic models (47). On the other hand, no human clinical trials have yet evaluated this combination, and potential pharmacodynamic overlaps raise uncertainty regarding safety. The U.S. Food and Drug Administration (FDA) currently classifies senolytic-metformin combinations as investigational under metabolic indications, pending formal Phase I-II trials. Another proposed regimen combines GLP-1 receptor agonists (e.g., liraglutide, semaglutide) with D+Q, leveraging enhanced glucose-dependent insulin secretion, reduced glucagon output, and weight loss alongside senolytic clearance of senescent adipocytes. Preclinical models have demonstrated improvements in B-cell function, decreased inflammatory cytokines, and enhanced metabolic resilience when these therapies are co-administered (5, 48). However, overlapping gastrointestinal adverse effects may reduce tolerability, and thiscombination remains untested in human subjects. Regulatory authorities, including the FDA and European Medicines Agency (EMA), currently consider such studies exploratory and have not granted approval for clinical evaluation. A third experimental combination involves Navitoclax, a BCL-2/BCL-xL inhibitor, used alongside SGLT2 inhibitors such as empagliflozin or dapagliflozin (49).
In animal models, this approach has been shown to induce apoptosis of senescent renal and adipose cells, decrease inflammation, and improve insulin sensitivity while simultaneously lowering blood glucose through renal glucose reabsorption blockade (50). However, translational progress is limited by Navitoclax-associated thrombocytopenia and neutropenia, adverse effects identified in early oncology trials. Both the FDA and EMA currently restrict Navitoclax to oncology investigational new drug (IND) programs due to these hematologic toxicities, underscoring the challenge of adapting it for metabolic applications. Another combination of interest is DPP-4 inhibitors (e.g., sitagliptin, linagliptin) with natural senolytics such as fisetin, which elevate incretin levels, enhance insulin secretion, and suppress glucagon, thereby improving overall glycemic control (51). Preclinical evidence suggests that combining DPP-4 inhibitors with fisetin amplifies anti-inflammatory and antioxidative effects in diabetic models. However, fisetin’s poor oral bioavailability and limited pharmacokinetic data hinder clinical translation, and the compound remains classified as a nutraceutical rather than a therapeutic agent by both FDA and EMA.
In summary, while these combination therapies represent a forward-looking strategy for integrating senotherapeutic and metabolic interventions, translation into clinical practice remains constrained by several key factors including but not limited to; the absence of long-term placebo-controlled studies, small and heterogeneous preclinical cohorts, and lack of validated glycemic endpoints.
Senolytic therapy in diabetes: preclinical and clinical insights
Human studies evaluating senolytic therapy in T2DM should be interpreted strictly as early-phase translational investigations. None were designed or powered to assess glycemic efficacy, disease modification, or long-term metabolic outcomes.
Animal models of T2DM treated with senolytics
Recent publications conducted on the therapeutic effects of senolytic agents on type 2 diabetes animal models showed a positive correlation in alleviating the symptoms and complications. In 2019, using a p16INK4a promoter potentially led to the improving of metabolic and adipose dysfunction (52). In 2022, another cocktail of drugs were used called mainly quercetin and dasatinib reviewed promising results in glucose and insulin resistance in obese mice which were transplanted with adipose tissue (53) while using a modified version of tamoxifen which targets mitochondria reduced appetite, adipogensis and senescent cells (54). Adding onto that, dasatinib when used has shown to reduce cardiac steatosis and fibrosis in diabetic mice models (55) and further studies conducted revealed improved wound healing with senolytic therapy on wound sites by inhibiting the senescent cell (56). in vivo and in vitro studies using fisetin had led to a positive effect in reducing aortic senescence and SASP factors (57).
Limitations of preclinical senolytic models in metabolic disease
Although preclinical studies consistently demonstrate improvements in insulin sensitivity, inflammatory burden, and β-cell preservation following senescent cell clearance, several important limitations warrant consideration.
First, metabolic phenotypes vary substantially across mouse models, including diet-induced obesity, leptin-deficient (ob/ob), and streptozotocin-induced diabetic models. These models differ in inflammatory tone, β-cell reserve, and immune response, limiting cross-model comparability.
Second, senolytic dosing paradigms in murine studies frequently employ intermittent high-dose regimens that may not translate directly to human pharmacokinetic constraints. The temporal dynamics of senescent cell clearance and repopulation remain incompletely characterized in metabolic tissues.
Third, endpoints are heterogeneous, ranging from glucose tolerance tests to surrogate inflammatory markers, with inconsistent measurement of durable HbA1c equivalents or long-term β-cell mass preservation.
Fourth, certain senolytic agents—particularly navitoclax—demonstrate dose-dependent thrombocytopenia due to BCL-xL inhibition in platelets, highlighting potential off-target toxicity.
Collectively, these limitations underscore that while mechanistic plausibility is strong, preclinical findings should be interpreted cautiously when extrapolating toward human metabolic disease.
Clinical trials and human studies
Systemic metabolic and biomarker studies- not powered for glycemic endpoints
There have been very few clinical trials conducted on humans that have been conducted that have concluded nonetheless, similar outcomes recorded in the animal models themselves. A very vital clinical trial conducted on humans was the use of a combination therapy of Dasatinib and Quercetin on obese patients with diabetic kidney disease which is a very common complication of long standing diabetes mellitus type 2, these participants received an oral therapy of the drugs for a course of 3 days and biopsies and blood samples were obtained 11 days after that to evaluate the effects (58). The results showed significant decrease in the burden exerted by the senescent cells on the subcutaneous adipose tissue, along with that it also showed reduced levels of senescence-associated secretory phenotype (SASP) factors circulating in the bloodstream which led us to infer that there is systemic anti-inflammatory benefits of using this drug and lastly, there were no side effects with the use of these drugs as it was a short course of treatment. Although the results seem very positive there are however a lot of limitations for the use of this study, the sampling size in which this therapy was used was only 9 people and there was no placebo kept for this specific research. Another very vital measurement left out was to check if the glycemia was controlled by the drug or not by checking the hbA1c or checking for insulin sensitivity. Last but not the least, this research mainly focuses on the complication and not on the effects it will have on diabetes type 2 mellitus as a whole.
Follow-up duration in available studies has ranged from 7 to 28 days, precluding assessment of sustained metabolic effects. Safety signals in early trials have generally been mild and transient; however, these studies were not powered to detect rare adverse events. Heterogeneity across trials reflects differences in patient populations (e.g., diabetic kidney disease vs. advanced age), dosing schedules, tissue endpoints, and absence of standardized metabolic outcome measures. These factors collectively limit interpretability and emphasize the need for harmonized trial design.
Organ-specific senolytic investigations
Another research that is quickly gaining popularity is the use of foselutoclax (a novel UBX1325) as a single dose intravitreal injection for patients with Type 2 Diabetes Mellitus-associated macular edema, this trial revealed that not only did the patients tolerate the drug well with no other complications it also showed an improvement in the patient’s visual acuity (59). The limitations of using this study does resemble the same challenges we faced above, with a small sampling size it’s not possible to generalize the whole population based on them. Table 3. Adding onto that, the use of senolytics although may show benefit for a short term, but the use of long term therapy and its efficacy still remains in the grey as more research is yet to be done.
This study evaluated ocular structural and visual endpoints and did not assess systemic glycemic control or metabolic parameters.
Importantly, no senolytic therapy has yet demonstrated clinical efficacy in improving HbA1c, insulin sensitivity, or long-term metabolic outcomes in individuals with T2DM. Existing human studies should be interpreted as evidence of biological target engagement rather than proof of therapeutic benefit. At present, senolytic therapy remains an experimental geroscience-based strategy requiring rigorous validation in adequately powered metabolic trials.
| Evidence level | Study type | Model/population | Senolytic intervention | Primary focus | Key findings | Translational status | Key limitations |
|---|---|---|---|---|---|---|---|
| Mechanistic | In vitro | Human and murine metabolic cells | Dasatinib, Quercetin, Navitoclax | SASP signaling and cell survival pathways | Reduction in SASP factors; restoration of insulin signaling pathways | Preclinical | Cell-based systems lack tissue and systemic context |
| Preclinical | Animal models | Obese and diabetic mouse models | Dasatinib + Quercetin; Navitoclax; Fisetin | Insulin sensitivity and β-cell function | Improved glucose tolerance; reduced inflammatory burden; partial β-cell preservation | Preclinical | Species-specific responses; dosing not directly translatable |
| Translational | Pilot clinical studies (Phase I) | Patients with T2DM and diabetic kidney disease | Dasatinib + Quercetin (short intermittent course) | Senescence biomarkers and SASP reduction | Decreased p16INK4a-positive cells and circulating inflammatory mediators | Early human validation | Small sample size; short duration; no glycemic endpoints |
| Organ-specific | Phase II randomized trials | Patients with diabetic macular edema | UBX1325 (BCL-xL inhibitor) | Organ-specific senescence outcomes | Improved visual acuity with acceptable short-term safety | Exploratory clinical | Non-glycemic endpoint; limited follow-up |
| Ongoing | Registered clinical trials | Older adults with metabolic disease | Fisetin; Navitoclax (investigational) | Safety and biomarker modulation | Trials ongoing; efficacy outcomes pending | Investigational | No published metabolic efficacy data yet |
Interpretive framework and evidence boundaries
Taken together, current human studies of senolytic therapy should be viewed as biological validation studies rather than efficacy trials. While reductions in senescence markers and inflammatory mediators are consistently observed, these surrogate outcomes do not yet translate into demonstrable improvements in glycemic control, insulin sensitivity, or β-cell preservation. The distinction between mechanistic promise and clinical effectiveness is critical, particularly in a heterogeneous disease such as T2DM.
Accordingly, senolytic therapy should presently be regarded as an experimental geroscience-based intervention, with potential relevance to metabolic disease that requires rigorous confirmation in adequately powered, randomized clinical trials using standardized metabolic endpoints. Until such data are available, claims regarding disease modification or glycemic benefit must remain provisional.
Integrative discussion and translational implications
This review synthesizes current evidence positioning cellular senescence as a biologically relevant contributor to metabolic dysfunction in T2DM. Rather than redefining T2DM exclusively as an aging disorder, we propose that senescence biology represents one upstream mechanistic layer interacting with established metabolic drivers such as obesity, insulin resistance, and glucotoxicity.
Integrative overview of mechanistic pathways
When viewed through the perspective of biological aging, type 2 diabetes mellitus (T2DM) is presented not only as a glucose metabolic disorder but also as a systemic condition, with a number of factors contributing to it including chronic cellular stress and maladaptive responses to aging. Cellular senescence presents an unifying mechanism, connecting metabolic overload, chronic inflammation, and tissue dysfunction in adipose tissue, liver, skeletal muscle, and pancreatic islets.
Rather than separate molecular anomalies, senescence-related pathways come together at the level of three interrelated mechanisms—sustained SASP-dependent inflammation, disruption of insulin receptor signaling, and impaired cellular regeneration. Several pro-inflammatory cytokines including IL-6, IL-1β, and TNF-α suppress insulin receptor substrate-1 (IRS-1) signaling, whereas chemokines and matrix-remodeling enzymes modify tissue architecture and enhance immune cell infiltration. In pancreatic β-cells, senescence limits proliferative capacity and accelerates functional exhaustion, amplifying glycemic dysregulation (Table 4).
| Pathway | Representative molecules | Metabolic consequences | Theraputic implication |
|---|---|---|---|
| Pro-inflammatory cytokine axis | IL-6, IL-1β, TNF-α, MCP-1 | Inhibits insulin receptor substrate (IRS-1) signaling; promotes hepatic gluconeogenesis | Targeted by senolytics and senomorphics to attenuate chronic inflammation |
| Fibrotic/remodeling mediators | MMP-9, PAI-1, TGF-β | Alters extracellular matrix and adipose remodeling, impairing insulin sensitivity | Reduced after D + Q or Fisetin therapy |
| Alarmin-oxidative stress loop | HMGB1, ROS, RAGE | Propagates mitochondrial stress, β-cell apoptosis | Potential target for antioxidant-based senomorphics (e.g., metformin, resveratrol) |
Clinical evidence in context: from mechanistic promise to translational caution
When interpreted within this aging-centered framework, the current human evidence for senolytic therapy assumes appropriate—but limited—significance. Existing clinical studies demonstrate biological target engagement, including reductions in senescence markers and circulating SASP components, thereby validating the mechanistic plausibility of senescent cell clearance in humans.
However, none of the available trials were designed to assess disease modification in T2DM. Sample sizes remain small, treatment durations short, and endpoints largely restricted to surrogate biomarkers or organ-specific outcomes. Importantly, no study has yet demonstrated durable improvements in HbA1c, insulin sensitivity, or β-cell preservation.
This distinction between mechanistic validation and clinical efficacy is critical. While senolytic therapy aligns conceptually with the aging-driven model of T2DM, its therapeutic relevance remains hypothetical until confirmed by adequately powered, randomized trials with standardized metabolic endpoints. The absence of proven glycemic efficacy should not be interpreted as failure of the senescence framework, but rather as a reflection of the early translational stage of this field (Table 5).
Collectively, these trials emphasize early safety and biomarker modulation, but none yet provide large-scale glycemic efficacy data or standardized metabolic endpoints.
| Trial ID | Phase/status | Intervention | Population | Primary endpoint |
|---|---|---|---|---|
| NCT02848131 | Phase I/II – Completed | Dasatinib + Quercetin | Idiopathic pulmonary fibrosis with metabolic comorbidities | Safety/senescence biomarkers |
| NCT04685590 | Phase II – Recruiting | UBX1325 (BCL-xL inhibitor) | Diabetic macular edema | Visual acuity/ocular senescence markers |
| NCT05249845 | Phase I – Recruiting | Fisetin (oral, 100 mg/day) | Older adults with T2DM | Changes in inflammatory cytokines and HbA1c |
| NCT05023682 | Phase I – Active | Navitoclax | Advanced metabolic syndrome | Dose-limiting toxicity and pharmacokinetics |
Pharmacodynamic and off-target considerations in an aging biology context
Targeting senescent cells introduces unique pharmacodynamic challenges that differ fundamentally from conventional antidiabetic therapies. Senolytics exert short-lived systemic exposure but induce prolonged biological effects through irreversible elimination of senescent cells. While this intermittent dosing paradigm is theoretically attractive, it also magnifies the importance of selectivity.
Early-generation senolytics such as navitoclax illustrate the tension between efficacy and toxicity, as BCL-xL inhibition affects both senescent cells and platelets. Similarly, dasatinib and quercetin display pleiotropic actions that may influence immune surveillance, mitochondrial function, and tissue repair. These considerations underscore that senescence is not uniformly pathological; it also plays essential roles in wound healing, tumor suppression, and immune regulation.
Consequently, therapeutic strategies must prioritize selective senescent cell targeting, tissue specificity, and intermittent exposure to minimize unintended disruption of beneficial senescence programs—particularly in older adults with multiple comorbidities.
Pharmacokinetic considerations are particularly relevant in T2DM populations characterized by polypharmacy, chronic kidney disease, hepatic steatosis, and cardiovascular comorbidities. Dasatinib is metabolized via CYP3A4, raising potential drug–drug interaction concerns with commonly prescribed statins, calcium channel blockers, and certain antihyperglycemic agents. Navitoclax-associated thrombocytopenia may be amplified in patients receiving antiplatelet or anticoagulant therapy, which are frequently used in individuals with diabetes and established atherosclerotic disease. Furthermore, altered renal clearance and hepatic metabolic capacity in diabetes may affect senolytic drug exposure, underscoring the need for population-specific dosing studies and formal pharmacokinetic evaluation in metabolically compromised patients.
Senolytics versus senomorphics: distinct roles in diabetes management
Within the aging-centered paradigm of T2DM, senolytics and senomorphics should be viewed as complementary rather than competing strategies. Senolytics aim to reduce senescent cell burden through targeted apoptosis, potentially resetting inflammatory and metabolic set points. In contrast, senomorphics suppress SASP production and modulate senescent cell behavior without inducing cell death.
Widely used antidiabetic agents such as metformin, GLP-1 receptor agonists, and SGLT2 inhibitors exhibit senomorphic properties, including attenuation of oxidative stress, enhancement of autophagy, and modulation of inflammatory signaling. These agents may therefore serve as long-term modulators of inflammaging, while senolytics—if proven safe and effective—could be deployed intermittently in carefully selected patients to reduce pathological senescent cell accumulation.
The Table 6 integrates molecular senescence pathways with corresponding metabolic consequences and therapeutic strategies, highlighting the mechanistic rationale, pharmacologic targeting approaches, and current translational maturity of senolytic and senomorphic interventions in type 2 diabetes mellitus.
| Senescence-associated pathway | Representative molecular drivers | Metabolic consequences in T2DM | Therapeutic strategy | Representative agents | Translational status |
|---|---|---|---|---|---|
| Pro-inflammatory SASP axis | IL-6, IL-1β, TNF-α, MCP-1 | Inhibition of IRS-1 signaling; increased hepatic gluconeogenesis; systemic insulin resistance | Senolytics (cell clearance) and Senomorphics (SASP suppression) | Dasatinib + Quercetin; Fisetin; Metformin | Early human biomarker studies; no glycemic efficacy data |
| Fibrotic and matrix remodeling pathway | MMP-9, MMP-12, PAI-1, TGF-β | Extracellular matrix remodeling; adipose dysfunction; β-cell microenvironment disruption | Predominantly Senolytics; partial modulation via senomorphics | D+Q; Navitoclax; GLP-1 receptor agonists (indirect anti-inflammatory effects) | Preclinical dominant; limited organ-specific human trials |
| Alarmin–oxidative stress loop | HMGB1, ROS, RAGE activation | Mitochondrial dysfunction; β-cell apoptosis; impaired regenerative capacity | Primarily Senomorphics; adjunct antioxidant approaches | Metformin; NADboosters; Resveratrol+ | Clinically established metabolic agents with geroprotective signals |
| SCAP survival signaling | BCL-2/BCL-xL, PI3K/AKT, p53/p21 | Persistence of senescent cell burden; chronic SASP amplification | Direct Senolytic targeting | Navitoclax; UBX1325; Dasatinib | Experimental; safety and selectivity concerns |
| Regenerative impairment pathway | p16INK4a, p21Cip1 upregulation | Reduced β-cell proliferative reserve; impaired tissue renewal | Precision-based intermittent senolysis | Investigational senolytics | Hypothesis-generating; requires randomized metabolic trials |
Translational outlook
Moving senolytic treatment from experimental geroscience to clinical diabetology will require a precision-medicine framework combining biological aging metrics with metabolic phenotyping. At the center of the endeavor is the development of validated senescence biomarkers that can quantify senescent cell burden, monitor therapeutic response, and differentiate pathological from adaptive senescence.
Integrated multi-omics techniques—transcriptomic, proteomic, and metabolomic profiling—fused with artificial intelligence (AI)-powered analytics present a valuable suite of tools for patient stratification, dose optimization, and toxicity prediction. Such approaches may also allow the identification of those for whom senescence-driven pathology predominates, maximizing benefit and minimizing risk.
In the end, large-scale randomized clinical trials incorporating aging-informed endpoints will ascertain if senolytic therapy can bring about meaningful alteration in the natural history of T2DM. Until such evidence emerges, senolytics should be considered investigational agents that shed light on a novel disease framework rather than established therapeutic.
Challenges and considerations
Senolytic therapy when used as a modality of treatment in treating type 2 diabetes mellitus does also pose serious challenges and considerations that we have to take into account when using them and as mentioned above there isn’t much research done or trials conducted to further evaluate the potential challenges that have been faced and how to overcome these obstacles, the Table 7 further explains it.
| Challenge / Consideration | Potential solution / Innovative approach | Evidence / References | Regulatory and policy perspective (FDA / EMA) | Risk–benefit framework |
|---|---|---|---|---|
| 1. Limited human clinical evidence | Conduct multicenter Phase II–III randomized controlled trials (e.g., Dasatinib + Quercetin) to establish long-term efficacy, optimal dosing, and safety. | (,) [59] [60] | FDA: Encourages IND submissions under metabolic / geroscience indications. EMA: Supports adaptive-pathway pilot trials once validated biomarkers are established. | Benefit: Proof-of-concept efficacy. Risk: Sparse longitudinal data and uncertain chronic safety. |
| 2. Off-target toxicity of early-generation senolytics | Develop mitochondria-targeted, self-assembling senolytic systems (integrin αvβ3, ROS-triggered activation) for selective elimination. | (,) [61] [62] | Regulators require tissue-specific selectivity and standardized toxicity assays before pivotal studies. | Benefit: Enhanced specificity. Risk: Potential mitochondrial stress in healthy cells. |
| 3. Non-specific drug release injuring normal cells | Engineer smart nanodevices (e.g., Navitoclax nanocarriers) activated by senescence-associated MMP-3 or ionizing-radiation cues. | () [63] | FDA / EMA: Stress validation of trigger mechanisms and low systemic exposure. | Benefit: Controlled release limits collateral damage. Risk: Nanomaterial immunogenicity or instability. |
| 4. Difficulty distinguishing senescent vs. quiescent cells | Apply Conditionally Active Biologics (CAB) targeting inflammatory microenvironments to spare non-senescent cells. | () [64] | Agencies recommend harmonized senescence-specific assays and avoidance of quiescent-cell depletion. | Benefit: Improved target precision. Risk: Context-dependent activation may limit efficacy. |
| 5. Suboptimal drug delivery and stability | Use “double-lock” nanoplatforms (β-galactosidase + acidic pH triggers) and micelle nanocarriers (e.g., GL392) for controlled release and enhanced stability. | (–) [65] [67] | Regulatory focus on reproducibility, nanocarrier stability, biodistribution, and manufacturing compliance (CMC). | Benefit: Improved pharmacokinetics and targeting. Risk: Complex production and cost. |
| 6. Off-target effects and systemic toxicity | Employ galactose-conjugated senolytic prodrugs cleaved only by senescence-associated biomarkers. | () [66] | Regulators require companion-diagnostic validation and risk-management monitoring. | Benefit: Reduced systemic toxicity. Risk: Inter-patient biomarker variability. |
| 7. Limited therapeutic scope beyond senolysis | Utilize pleiotropic agents (e.g., Quercetin) for antioxidant, neuroprotective, and anti-inflammatory effects. | () [60] | Broader indication acceptable if mechanism and safety are well defined. | Benefit: Broader metabolic protection. Risk: Mechanistic ambiguity in efficacy. |
| 8. Need for improved stability and efficacy | Combine lipofuscin-binding scaffolds with micelle nanocarriers to optimize bioavailability and potency. | () [67] | Regulatory bodies expect proof of formulation stability and cross-species safety. | Benefit: Sustained efficacy with lower doses. Risk: Unknown long-term tissue accumulation. |
| 9. Regulatory uncertainty and lack of harmonized biomarker frameworks | Develop multi-omics and AI-based models to define senescence signatures and enable precision stratification. | — | FDA / EMA: Jointly promote AI-assisted biomarker qualification, adaptive trials, and post-market pharmacovigilance. | Benefit: Accelerated approval and better patient selection. Risk: Data-privacy and model-transparency issues. |
| 10. Comprehensive risk–benefit assessment for translation | Integrate precision-medicine analytics (genomics, proteomics, metabolomics, AI) to predict responders and adverse events. | — | Supported under the emerging Geroscience Regulatory Framework and adaptive licensing schemes. | Overall Benefit: Reduced senescence burden, better metabolic control, health-span extension. Overall Risk: Uncertain chronic toxicity, cost, and ethical implications of lifespan modulation. |
Translational and regulatory changes
Translation of senolytic therapies into clinical diabetology faces several regulatory and practical challenges. Current human evidence remains limited to small, early-phase studies primarily evaluating safety and biomarker modulation. Larger multicenter randomized trials are required to establish long-term efficacy, optimal dosing strategies, and metabolic endpoints relevant to T2DM.
Off-target toxicity remains a concern, particularly with first-generation agents such as navitoclax, where thrombocytopenia has limited broader clinical development. Regulatory authorities appropriately require demonstration of tissue selectivity, reproducible biomarker validation, and acceptable safety margins before advancing metabolic indications.
Additional challenges include the absence of standardized senescence biomarkers, heterogeneity of T2DM phenotypes, and the need for precision-based patient stratification. While emerging approaches involving multi-omics profiling and AI-assisted analytics may support future trial design, these remain investigational and should be interpreted cautiously.
Accordingly, senolytic therapy currently occupies an exploratory position within geroscience-informed endocrinology rather than an established therapeutic pathway.
Safety and ethical concerns
Although there has been extensive light shed on senolytic therapy for its potential to treat Type 2 Diabetes Mellitus, there has however been a lot of concerns to address based on its safety and its toxicity side effects. A research concluded that when an older mouse model infected in Influenza A virus treated with any senolytic therapy like dasatinib and quercetin showed no improvement in survival or weight loss which led us to infer that senolytic treatments may not pose any effect if used on elderly with associated influenza A virus. Additionally, the research also concluded that when treatment like dasatinib and quercetin were administered it further suppressed the immune cell infiltration so it also led us to infer that it may exacerbate the immune response (68). Although the benefits do seem to outweigh the risk, since this discovery is relatively new and does not have much evidence to back the long term use of these therapies, the variability of senescent cell reaction to the drug differs drastically from species to species (69). Another potential concern to address is informed consent, as using these newly discovered drugs may have unknown side effects not yet studied and this in turn makes it harder to obtain informed consent in vulnerable populations like patients with diabetes (70). A very vital problem to tackle is the cost incurred on the patients end, as senolytics is a new branch in medicine the cost is usually higher when compared to other drugs. This in turn may lead to a disparity that the low-income groups cannot afford and raises ethical concerns based on fairness in treating the same condition (71). Another ethical concern does arise when we talk about unintended physiological consequences of using this therapy. Senescent cells play a crucial role in maintaining the immune system and in tissue repair, the removal of these may result in an increase in the chance of getting cancer or may cause immunosuppression. This could potentially pose ethical dilemmas about the harm versus the benefit of the use of senolytic therapy in treating Type 2 Diabetes Mellitus.
Future directions and research gaps
Senolytic therapy is an emerging field with promising but preliminary evidence to suggest the benefits, and significant knowledge gaps remain before clinical application. Preclinical and early clinical findings highlight the clear need for large-scale stage II, III randomized controlled trials to clinically establish efficacy in humans and tailor doses as well as test long-term safety. While short-term advantages have been repeatedly reported, the long-term safety of senolytics is still unknown, including drug–drug interaction sparing and their effects on individuals with multiple comorbidities.
One of the obstacles in this respect is that no universal biomarkers are available to precisely measure senescent cell burden, follow therapeutic progress and apply precision medicine. Since T2DM is a heterogeneous disease so one size does not fit all will be ideal. A multi-omics and artificial intelligence (AI)-powered approach, instead, is more likely to be recognized as crucial for uncovering senescence-related molecular signatures and stratifying patients into biologically relevant subclasses. Integrative analysis of transcriptome, proteome, metabolome and epigenome data retrieved by machine learning models can further identify the hidden senescence-related patterns associated with metabolic impairment, inflammatory response and drug response. They have the potential not only to provide fine-tuning of patient selection for senolytic therapy but also to discover new therapeutic and predictive targets.
Therefore, the future of senolytic therapy in diabetes rests on a multidisciplinary precision-medicine approach although currently senolytic therapy is currently being viewed as a biologically informative experimental strategy that advances disease modeling and patient stratification paradigms, rather than a clinically deployable treatment modality.
Biological and clinical uncertainties
While accumulating evidence supports the mechanistic plausibility of targeting senescent cells in metabolic disease, several biological uncertainties warrant careful consideration.
First, senescence is context-dependent and may exert protective roles in tumor suppression, wound healing, and tissue remodeling. Indiscriminate clearance of senescent cells could theoretically impair regenerative responses or immune surveillance.
Second, certain models suggest that transient senescence may facilitate adaptive metabolic remodeling. Complete ablation may therefore not uniformly confer benefit.
Third, immune modulation following senolytic exposure remains incompletely understood, particularly in older adults with multimorbidity. Potential risks include impaired pathogen defense or altered oncologic risk.
Fourth, several preclinical studies have demonstrated modest or variable metabolic improvements, indicating that senescence may represent one contributory mechanism rather than a universal driver of T2DM.
Accordingly, senolytic therapy must be evaluated within a rigorous risk–benefit framework, emphasizing selectivity, tissue targeting, and biomarker-guided stratification.
Conclusion
Cellular senescence represents a biologically relevant contributor to the pathogenesis of type 2 diabetes mellitus (T2DM), primarily through sustained senescence-associated secretory phenotype (SASP)-mediated inflammation and impaired tissue regenerative capacity. Chronic metabolic stressors—including aging, obesity, hyperglycemia, oxidative stress, and mitochondrial dysfunction—promote senescent cell accumulation in adipose tissue, liver, and pancreatic β-cells, where persistent SASP signaling disrupts insulin receptor pathways and accelerates β-cell functional decline. Preclinical models consistently demonstrate metabolic improvement following senescent cell clearance; however, current human evidence is limited to early-phase studies evaluating biomarker modulation and short-term safety rather than glycemic efficacy.
Despite compelling mechanistic plausibility, no senolytic intervention has yet demonstrated sustained improvement in HbA1c, insulin sensitivity, or long-term clinical outcomes in T2DM. Larger, adequately powered randomized trials incorporating standardized metabolic endpoints are required before therapeutic claims can be substantiated (72).